Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Recurrence of hepatitis C virus infection during pityriasis rosea.

Drago F, Javor S, Parodi A.

Acta Derm Venereol. 2013 Jul 6;93(4):483. doi: 10.2340/00015555-1509. No abstract available.

2.

Occult hepatitis B virus infection in patients with chronic hepatitis C: An actor behind the scene or just a bystander?

Chu CJ, Lee SD.

J Gastroenterol Hepatol. 2010 Feb;25(2):221-3. doi: 10.1111/j.1440-1746.2009.06134.x. No abstract available.

PMID:
20136983
3.

Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.

Bader el-Din NG, Abd el-Meguid M, Tabll AA, Anany MA, Esmat G, Zayed N, Helmy A, el-Zayady AR, Barakat A, el-Awady MK.

J Gastroenterol Hepatol. 2011 Jan;26(1):55-62. doi: 10.1111/j.1440-1746.2010.06319.x.

PMID:
21175794
4.

Sustained virological response: a milestone in the treatment of chronic hepatitis C.

Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N.

World J Gastroenterol. 2013 May 14;19(18):2793-8. doi: 10.3748/wjg.v19.i18.2793.

5.

Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.

Chen LW, Chien RN, Yen CL, Chang JJ, Liu CJ, Lin CL.

J Gastroenterol Hepatol. 2010 Feb;25(2):259-63. doi: 10.1111/j.1440-1746.2009.06006.x. Epub 2009 Oct 9.

PMID:
19817959
6.

Viral response guided therapy for hepatitis C in the approaching era of direct acting anti-viral agents.

Berzsenyi MD, Roberts SK.

J Gastroenterol Hepatol. 2010 Apr;25(4):655-6. doi: 10.1111/j.1440-1746.2010.06283.x. No abstract available.

PMID:
20492322
7.

Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy.

Saitta C, Pontisso P, Brunetto MR, Fargion S, Gaeta GB, Niro GA, Picciotto A, Smedile A, Squadrito G, Raimondo G.

Antivir Ther. 2006;11(7):931-4.

PMID:
17302256
8.

Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C.

Soriano V, Vispo E, de Mendoza C, Labarga P, Plaza Z, Fernandez-Montero JV, Poveda E, Treviño A, Barreiro P.

Antivir Ther. 2013;18(8):1033-5. doi: 10.3851/IMP2659. Epub 2013 Jun 27.

PMID:
23804629
9.

Peginterferon and ribavirin for chronic hepatitis C.

Hoofnagle JH, Seeff LB.

N Engl J Med. 2006 Dec 7;355(23):2444-51. Review. No abstract available.

PMID:
17151366
10.

Hepatitis C virus: five-year follow-up of patients with sustained virological response.

Urquijo JJ, Diago M.

Rev Esp Enferm Dig. 2011 Feb;103(2):53-5. No abstract available.

11.

Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.

Biermer M, Berg T.

Gastroenterology. 2009 Jul;137(1):390-1. doi: 10.1053/j.gastro.2009.02.087. Epub 2009 May 30. No abstract available.

PMID:
19486953
12.

Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.

Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Dhillon AP, Alsiö A, Hellstrand K, Westin J, Christensen P, Leutscher P, Norkrans G; NORDynamIC Study Group.

Hepatology. 2008 Aug;48(2):695. doi: 10.1002/hep.22450. No abstract available.

PMID:
18666232
13.

Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.

Knop V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Neumann K, Sarrazin C, Zeuzem S, Berg T.

Ann Hepatol. 2013 Mar-Apr;12(2):190-8.

14.

Impact of occult hepatitis B virus infection or hepatitis B virus DNA integration on efficacy of chronic hepatitis C treatment with peginterferon and ribavirin: where are we?

Hu KQ, Zhang YY.

J Clin Gastroenterol. 2014 Jan;48(1):3-5. doi: 10.1097/MCG.0b013e3182a6633d. No abstract available.

PMID:
24045272
15.

Pegylated interferon treatment in HCV genotype 2 and 3 patients refractory to conventional interferon.

Aziz S.

J Coll Physicians Surg Pak. 2012 Oct;22(10):615-6. doi: 10.2012/JCPSP.615616. No abstract available.

PMID:
23058141
16.

Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.

Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Yoshioka K, Toyoda H, Kumada T, Goto H.

Liver Int. 2011 Oct;31(9):1359-65. doi: 10.1111/j.1478-3231.2011.02571.x. Epub 2011 Jun 23.

PMID:
21745312
17.

Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.

Namikawa M, Kakizaki S, Yata Y, Yamazaki Y, Horiguchi N, Sato K, Takagi H, Mori M.

J Gastroenterol Hepatol. 2012 Jan;27(1):69-75. doi: 10.1111/j.1440-1746.2011.06802.x.

PMID:
21649727
18.

[Treatment of chronic hepatitis C].

Fehér J, Lengyel G.

Orv Hetil. 2004 May 16;145(20):1065-7. Review. Hungarian. No abstract available.

PMID:
15202329
19.

Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.

Gholam PM.

N Engl J Med. 2004 Nov 25;351(22):2340-2; author reply 2340-2. No abstract available.

PMID:
15570682
20.

ADVANCE study begins enrollment.

[No authors listed]

AIDS Patient Care STDS. 2008 Apr;22(4):345. doi: 10.1089/apc.2008.9957. No abstract available.

PMID:
18422463

Supplemental Content

Support Center